Durham, NC-September 24, 2009 Health Decisions introduced the next phase of its recently launched HD360° trial management platform: Monitor View, the second of three modules that will complete the system. The new module promotes more strategic, proactive trial management and aims to reduce monitors’ time and travel expenses.
With this upgrade, monitors from both Health Decisions and sponsor companies can perform tasks and access information through a simplified, customizable Web environment that features search and reporting tools and automated resolution of some query types. HD360° Monitor View also schedules site monitoring visits based on the quantity of work amassed at each individual site, instead of according to a pre-ordained schedule. This is meant to reduce travel time and expense while promoting faster, more organized database locks. In addition to basic trial information, HD360° Monitor View also tracks site performance metrics
According to Health Decisions COO Rick Farris, this approach is Monitor View’s key benefit and the basis of the HD360° system.
“For a clinical trial to be truly efficient, every person working on it must have access to the right information-which includes both performance data and meaningful analysis-as quickly as possible,” said Farris.
It aligns seamlessly with HD360° Investigator View, released earlier this summer. The final module Sponsor View is scheduled for release next year and will feature enhanced reporting and analysis tools for sponsors.
“The HD360° system creates one central control hub for the collection, management and analysis of all clinical data and metrics,” said Maurice Hagar, head of IT at Health Decisions. “Each study role-investigator site, monitor, sponsor and every function in between-will be equipped with information to more actively contribute to the study’s overall success.”
Coinciding with Monitor View’s integration into the HD360° system, Health Decisions also added upgrades to HD360° Investigator View. The upgrades are based on feedback from the four investigator sites participating in the initial launch, and include sleeker reports, enhanced search filters for locating queries and subjects, more targeted metrics, and enhanced security and password recovery options.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.